Top 10 Building Product Stocks To Watch Right Now: Ibio Inc (IBIO)
iBio, Inc. (iBio), incorporated on April 17, 2008, is a biotechnology company focused on commercializing its technologies, the iBioLaunch platform for vaccines and therapeutic proteins, as well as the iBioModulator platform for vaccine enhancement. Vaccine candidates on its platform are applicable to newly emerging strains of hemagglutinin type 1 and neuraminidase type 1 (H1N1), swine-like influenza, hemagglutinin type 5 and neuraminidase type 1 (H5N1) avian influenza, yellow fever, and anthrax. The Company licenses or otherwise grants use rights to government and non-governmental organization (NGO) entities for not-for-profit applications of the intellectual property for the development or application for which they granted or were granted funding, and to Fraunhofer USA, Inc. (FhCMB) for research purposes and applications in other fields.
The Companys platform technology is referred to as iBioLaunch technology or the iBioLaunch platform, and the category o f this technology is referred to as plant-based technology or as a plant-based platform. The Company has exclusive control over, and the rights to ownership of, the intellectual property related to all human health and veterinary influenza applications of the plant-based technology developed by FhCMB. Its property consists of the technology platform pursuant, to which hydroponically grown green plants can be used for the accelerated development and manufacture of high-value proteins of interest as candidate therapeutic products and vaccines applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus (HPV), and veterinary influenza applications.
Through FhCMB and their funding from the Bill & Melinda Gates Foundation, it is developing vaccine candidates targeting pathogenic avian influenza (H5N1) viruses based upon the iBioLaunch platform. These candidates have demonstrated immunogenicity an! d have been succ essfully tested in mice and ferrets for protective efficacy. Like its candidate vaccines for seasonal influenza, its candidate vaccines for avian influenza are subunit vaccines. iBio has commercial rights to vaccine candidates developed pursuant to its business structure based on fusing a protein component of HPV called the E7 antigen, to the LicKM protein of the bacterium Clostridium thermocellum. It has commercial rights to an oral anthrax booster vaccine candidate developed by FhCMB in collaboration with the Naval Medical Research Center (NMRC).Advisors' Opinion:
- [By Bryan Murphy]
If the name Ibio Inc. (NYSEMKT:IBIO) rings a bell, it may be because I put some bullish thoughts into print regarding the stock back on June 21st. I reiterated my optimism on July 12th. What can I say? It's fun to be right. IBIO shares have advanced 17% since my first look in late June. Then again, most of that big jump has unfurled in the last couple of days, meaning Ibio Inc. is overbought. Do we trust the breakout move, or do we fear a pullback? Answer: That depends.
- [By James E. Brumley]
With just a quick glance, Ibio Inc. (NYSEMKT:IBIO) doesn't look like anything particularly special. The stock's just bouncing around, and we've not heard any particularly meaningful news from IBIO in a few weeks.
source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-10-building-product-stocks-to-watch-right-now-2.html